EOX regimen
|
WikiDoc Resources for EOX regimen |
|
Articles |
|---|
|
Most recent articles on EOX regimen Most cited articles on EOX regimen |
|
Media |
|
Powerpoint slides on EOX regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on EOX regimen at Clinical Trials.gov Clinical Trials on EOX regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on EOX regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on EOX regimen Discussion groups on EOX regimen Patient Handouts on EOX regimen Directions to Hospitals Treating EOX regimen Risk calculators and risk factors for EOX regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for EOX regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
EOX regimen refers to a regimen consisting of epirubicin, oxaliplatin, capecitabine (xeloda) used to treat advanced oesophagogastric cancer.[1]
Regimen
EEpirubicin
OOxaliplatin
XCapecitabine (xeloda)
Indications
References
- ↑ 1.0 1.1 Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR; et al. (2005). "Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF". Br J Cancer. 92 (11): 1976–83. doi:10.1038/sj.bjc.6602572. PMC 2361798. PMID 15928658.